Top

Published in:

01-03-2016 | Prostate Cancer (A Kibel, Section Editor)

Prostate Cancer Imaging with Novel PET Tracers

Authors: Liza Lindenberg, Peter Choyke, William Dahut

Published in: Current Urology Reports | Issue 3/2016

Abstract

Molecular imaging of prostate cancer is in a dynamic phase of development. Currently approved techniques are limited and researchers have been working on novel agents to improve accuracy in targeting and detecting prostate tumors. In addition, the complexity of various prostate cancer states also contributes to the challenges in evaluating suitable radiotracer candidates. We have highlighted nuclear medicine tracers that focus on mechanisms involved in bone metastasis, prostate cancer cell membrane synthesis, amino acid analogs, androgen analogs, and the prostate specific membrane antigen. Encouraging results with many of these innovative radiotracer compounds will not only advance diagnostic capabilities for prostate cancer but open opportunities for theranostic applications to treat this worldwide malignancy.

Ferlay J, S.I., Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. 2013. Available from: http://globocan.iarc.fr 3/20/2014].

Hillner BE et al. Impact of F-18-fluoride PET in patients with known prostate cancer: initial results from the National Oncologic PET Registry. J Nucl Med. 2014;55(4):574–81.CrossRefPubMed

Hillner BE et al. 18F-fluoride PET used for treatment monitoring of systemic cancer therapy: results from the National Oncologic PET Registry. J Nucl Med. 2015;56(2):222–8.CrossRefPubMed

Sampath SC et al. Detection of osseous metastasis by F-18-NaF/F-18-FDG PET/CT versus CT alone. Clin Nucl Med. 2015;40(3):E173–7.CrossRefPubMed

Simoncic U et al. Comparison of NaF and FDG PET/CT for assessment of treatment response in castration-resistant prostate cancers with osseous metastases. Clin Genitourin Cancer. 2015;13(1):E7–17.PubMedCentralCrossRefPubMed

6.••

Etchebehere E. et al. Prognostic factors in patients treated with radium-223: the role of skeletal tumor burden on baseline 18F-fluoride-PET/CT in predicting overall survival. J Nucl Med. 2015. This paper describes how NaF can be a predictive biomarker for overall survival and skeletal related events in patients treated with Ra.

Yu EY et al. Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687. J Nucl Med. 2015;56(3):354–60.PubMedCentralCrossRefPubMed

Poulsen MH et al. Spine metastases in prostate cancer: comparison of technetium-99m-MDP whole-body bone scintigraphy, F-18 choline positron emission tomography(PET)/computed tomography (CT) and F-18 NaF PET/CT. BJU Int. 2014;114(6):818–23.CrossRefPubMed

Swinnen JV et al. Fatty acid synthase drives the synthesis of phospholipids partitioning into detergent-resistant membrane microdomains. Biochem Biophys Res Commun. 2003;302(4):898–903.CrossRefPubMed

10.

Madigan AA et al. Novel nuclear localization of fatty acid synthase correlates with prostate cancer aggressiveness. Am J Pathol. 2014;184(8):2156–62.PubMedCentralCrossRefPubMed

11.

Mena E et al. 11C-Acetate PET/CT in localized prostate cancer: a study with MRI and histopathologic correlation. J Nucl Med. 2012;53(4):538–45.PubMedCentralCrossRefPubMed

12.

Mohsen B et al. Application of C-11-acetate positron-emission tomography (PET) imaging in prostate cancer: systematic review and meta-analysis of the literature. BJU Int. 2013;112(8):1062–72.CrossRefPubMed

13.

Haseebuddin M et al. 11C-acetate PET/CT before radical prostatectomy: nodal staging and treatment failure prediction. J Nucl Med. 2013;54(5):699–706.PubMedCentralCrossRefPubMed

14.

Leisser A. et al. Evaluation of fatty acid synthase in prostate cancer recurrence: SUV of [C]acetate PET as a prognostic marker. Prostate. 2015.

15.

Dusing RW et al. Prostate-specific antigen and prostate-specific antigen velocity as threshold indicators in 11C-acetate PET/CTAC scanning for prostate cancer recurrence. Clin Nucl Med. 2014;39(9):777–83.PubMedCentralCrossRefPubMed

16.

Umbehr MH et al. The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol. 2013;64(1):106–17.CrossRefPubMed

17.

Evangelista L et al. Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis. Clin Nucl Med. 2013;38(5):305–14.CrossRefPubMed

18.•

Beheshti M et al. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics. J Nucl Med. 2013;54(6):833–40. This large prospective trial looked at FCH in BCR patients and examined its relationship to PSA and ADT.CrossRefPubMed

19.

Castellucci P et al. Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy? J Nucl Med. 2014;55(9):1424–9.CrossRefPubMed

20.

Wondergem M et al. A literature review of 18F-fluoride PET/CT and 18F-choline or 11C-choline PET/CT for detection of bone metastases in patients with prostate cancer. Nucl Med Commun. 2013;34(10):935–45.CrossRefPubMed

21.

Piccardo A et al. Value of fused 18F-Choline-PET/MRI to evaluate prostate cancer relapse in patients showing biochemical recurrence after EBRT: preliminary results. BioMed Res Int. 2014;2014:103718.PubMedCentralCrossRefPubMed

22.

Ceci F et al. Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial (vol 41, pg 2222, 2014). Eur J Nucl Med Mol Imaging. 2014;41(12):2359.CrossRef

23.

Giovacchini G et al. C-11-Choline PET/CT predicts prostate cancer-specific survival in patients with biochemical failure during androgen-deprivation therapy. J Nucl Med. 2014;55(2):233–41.CrossRefPubMed

24.

Turkbey B et al. Localized prostate cancer detection with F-18 FACBC PET/CT: comparison with MR imaging and histopathologic analysis. Radiology. 2014;270(3):849–56.PubMedCentralCrossRefPubMed

25.

Nanni C et al. 18F-FACBC compared with 11C-choline PET/CT in patients with biochemical relapse after radical prostatectomy: a prospective study in 28 patients. Clin Genitourin Cancer. 2014;12(2):106–10.CrossRefPubMed

26.

Schuster DM et al. Anti-3-F-18 FACBC positron emission tomography-computerized tomography and In-111-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial. J Urol. 2014;191(5):1446–53.PubMedCentralCrossRefPubMed

27.

Ren J. et al. The value of anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT in the diagnosis of recurrent prostate carcinoma: a meta-analysis. Acta Radiol. 2015.

28.

Beattie BJ et al. Pharmacokinetic assessment of the uptake of 16 beta-F-18-fluoro-5 alpha-dihydrotestosterone (FDHT) in prostate tumors as measured by PET. J Nucl Med. 2010;51(2):183–92.PubMedCentralCrossRefPubMed

29.

Larson SM et al. Tumor localization of 16 beta-F-18-fluoro-5 alpha-dihydrotestosterone versus F-18-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med. 2004;45(3):366–73.PubMed

30.

Vargas HA et al. Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival. Radiology. 2014;271(1):220–9.PubMedCentralCrossRefPubMed

31.

Rathkopf DE et al. Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2013;31(28):3525–30.PubMedCentralCrossRefPubMed

32.

Bertolini R et al. 18F-RB390: innovative ligand for imaging the T877A androgen receptor mutant in prostate cancer via positron emission tomography (PET). Prostate. 2015;75(4):348–59.CrossRefPubMed

33.

Osborne JR et al. A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy. J Urol. 2014;191(5):1439–45.PubMedCentralCrossRefPubMed

34.

Pandit-Taskar N. et al. A phase I/II study for analytic validation of 89Zr-J591 immunoPET as a molecular imaging agent for metastatic prostate cancer. Clin Cancer Res. 2015.

35.

Vallabhajosula S. et al. Radioimmunotherapy of metastatic prostate cancer with 177Lu-DOTA-huJ591 anti prostate specific membrane antigen specific monoclonal antibody. Curr Radiopharm. 2015.

36.

Zechmann CM et al. Radiation dosimetry and first therapy results with a I-124/I-131-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014;41(7):1280–92.PubMedCentralCrossRefPubMed

37.•

Afshar-Oromieh A et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42(2):197–209. This study included a large cohort of patients undergoing 68Ga to detect recurrent cancer with histologic corroboration in 42 patients. PubMedCentralCrossRefPubMed

38.

Eiber M et al. Evaluation of hybrid (6)(8)Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56(5):668–74.CrossRefPubMed

39.

Giesel FL. et al. PSMA PET/CT with Glu-urea-Lys-(Ahx)-[Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015.

40.

Budaus L. et al. Initial Experience of Ga-PSMA PET/CT Imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur Urol. 2015.

41.

Afshar-Oromieh A et al. Comparison of PET imaging with a Ga-68-labelled PSMA ligand and F-18-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41(1):11–20.PubMedCentralCrossRefPubMed

42.••

Morigi JJ et al. Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med. 2015;56(8):1185–90. This is a prospective study comparing the two tracers in patients with BCR and how they affected management. CrossRefPubMed

43.

Ceci F et al. (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging. 2015;42(8):1284–94.CrossRefPubMed

44.

Maurer T et al. Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer. Eur Urol. 2015;68(3):530–4.CrossRefPubMed

45.

Hijazi S. et al. Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by Ga-PSMA-positron emission tomography/computerized tomography. Prostate. 2015.

46.

Afshar-Oromieh A. et al. The novel theranostic PSMA-ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry and first evaluation of tumor lesions. J Nucl Med. 2015.

47.

Ahmadzadehfar H et al. Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res. 2015;5(1):114.PubMed

48.

Rowe SP et al. (1)(8)F-DCFBC PET/CT for PSMA-based detection and characterization of primary prostate cancer. J Nucl Med. 2015;56(7):1003–10.PubMedCentralCrossRefPubMed

49.

Szabo Z et al. Initial evaluation of [(18)F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol. 2015;17(4):565–74.PubMedCentralCrossRefPubMed

50.•

Dietlein M et al. Comparison of [(18)F]DCFPyL and [(68)Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Mol Imaging Biol. 2015;17(4):575–84. This prospective trial evaluated the leading PSMA agents in detecting BCR and found them to be comparable. PubMedCentralCrossRefPubMed

Title: Prostate Cancer Imaging with Novel PET Tracers
Authors: Liza Lindenberg
Peter Choyke
William Dahut
Publication date: 01-03-2016
Publisher: Springer US
Published in: Current Urology Reports / Issue 3/2016
Print ISSN: 1527-2737
Electronic ISSN: 1534-6285
DOI: https://doi.org/10.1007/s11934-016-0575-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Prostate Cancer Imaging with Novel PET Tracers

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2016

Novel Technologies in Urologic Surgery: a Rapidly Changing Scenario

A Review Comparing Experience and Results with Bipolar Versus Monopolar Resection for Treatment of Bladder Tumors

Evolving Guidance on Ureteric Calculi Management in the Acute Setting

Contemporary Status of Percutaneous Ablation for the Small Renal Mass

Underactive Bladder

Pelvic Prolapse Repair in the Era of Mesh